CDMO - Avid Bioservices Inc Stock Price, Fair Value and News

9.12USD-0.08 (-0.87%)Delayed

Market Summary

USD9.12-0.08

Delayed

-0.87%

CDMO Alerts

Point72 Asset Management, L.P. reported owning 5.1% of CDMO [2024-04-26]

CDMO Stock Price

View Fullscreen

CDMO RSI Chart

CDMO Valuation

Market Cap

578.9M

Price/Earnings (Trailing)

-32.19

Price/Sales (Trailing)

4.23

EV/EBITDA

-70.18

Price/Free Cashflow

-15.04

CDMO Price/Sales (Trailing)

CDMO Profitability

Operating Margin

59.54%

EBT Margin

-15.47%

Return on Equity

-9.98%

Return on Assets

-3.95%

Free Cashflow Yield

-6.65%

CDMO Fundamentals

CDMO Revenue

Revenue (TTM)

136.7M

Rev. Growth (Yr)

-11.06%

Rev. Growth (Qtr)

33.16%

CDMO Earnings

Earnings (TTM)

-18.0M

Earnings Growth (Yr)

-2.3K%

Earnings Growth (Qtr)

36.92%

Breaking Down CDMO Revenue

Last 7 days

5.2%

Last 30 days

35.9%

Last 90 days

21.6%

Trailing 12 Months

-37.5%

How does CDMO drawdown profile look like?

CDMO Financial Health

Current Ratio

0.46

CDMO Investor Care

Shares Dilution (1Y)

1.49%

Diluted EPS (TTM)

-0.28

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	136.7M	0	0	0
2023	140.7M	149.3M	150.3M	140.9M
2022	116.0M	119.6M	125.5M	134.2M
2021	80.8M	95.9M	101.2M	106.3M
2020	64.2M	59.7M	69.8M	72.6M
2019	43.5M	53.6M	56.3M	64.4M
2018	64.6M	53.6M	39.1M	36.5M
2017	58.5M	57.6M	79.1M	68.5M
2016	35.2M	44.7M	40.6M	54.5M
2015	23.9M	26.8M	31.0M	34.2M
2014	20.2M	22.4M	23.2M	22.2M
2013	19.5M	21.7M	22.1M	23.3M
2012	15.9M	15.2M	13.8M	15.7M
2011	17.1M	13.5M	15.9M	15.5M
2010	0	27.9M	24.3M	20.7M

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Avid Bioservices Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 30, 2024	hart daniel r	sold	-20,910	7.3993	-2,826	chief financial officer
Apr 30, 2024	richieri richard a.	sold	-7,436	7.3995	-1,005	chief operations officer
Apr 30, 2024	kwietniak matthew r.	sold	-9,121	7.3982	-1,233	chief commercial officer
Apr 30, 2024	ziebell mark r	sold	-12,157	7.3993	-1,643	v. p., general counsel
Apr 30, 2024	green nicholas stewart	sold	-87,028	7.3991	-11,762	president & ceo
Apr 30, 2024	richieri richard a.	sold	-806	7.4	-109	chief operations officer
Apr 11, 2024	kwietniak matthew r.	acquired	-	-	669	chief commercial officer
Apr 09, 2024	kwietniak matthew r.	acquired	-	-	2,532	chief commercial officer
Apr 09, 2024	hart daniel r	acquired	-	-	5,742	chief financial officer
Apr 09, 2024	ziebell mark r	acquired	-	-	3,208	v. p., general counsel

Which funds bought or sold CDMO recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	reduced	-5.01	-9,032	423,179	-%
May 16, 2024	Beacon Capital Management, LLC	new	-	456	456	-%
May 16, 2024	Pineridge Advisors LLC	reduced	-80.62	-1,342	335	-%
May 16, 2024	JANE STREET GROUP, LLC	added	572	2,900,660	3,389,360	-%
May 16, 2024	COMERICA BANK	reduced	-7.5	-274	5,624	-%
May 16, 2024	Ancora Advisors LLC	new	-	6,700	6,700	-%
May 16, 2024	AWM Investment Company, Inc.	reduced	-25.53	-1,407,280	4,647,650	0.61%
May 15, 2024	Portolan Capital Management, LLC	added	97.65	2,957,220	5,808,130	0.44%
May 15, 2024	272 Capital LP	added	39.66	1,479,880	5,426,950	2.17%
May 15, 2024	Point72 Asia (Singapore) Pte. Ltd.	added	89.7	35,924	73,523	0.02%

Are Funds Buying or Selling CDMO?

Are funds buying CDMO calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own CDMO

No. of Funds

CDMO Alerts

Point72 Asset Management, L.P. reported owning 5.1% of CDMO [2024-04-26]

Unveiling Avid Bioservices Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 26, 2024	point72 asset management, l.p.	5.1%	3,226,006	SC 13G
Feb 14, 2024	t. rowe price investment management, inc.	6.9%	4,352,252	SC 13G
Feb 13, 2024	vanguard group inc	5.72%	3,617,873	SC 13G/A
Jan 26, 2024	altravue capital, llc	4.70%	2,974,333	SC 13G/A
Jan 25, 2024	state street corp	7.57%	4,784,239	SC 13G/A
Jan 08, 2024	blackrock inc.	8.4%	5,281,444	SC 13G/A
Jan 08, 2024	integrated core strategies (us) llc	4.8%	3,022,321	SC 13G/A
Dec 19, 2023	integrated core strategies (us) llc	5.1%	3,200,730	SC 13G
Feb 14, 2023	t. rowe price investment management, inc.	5.8%	3,607,653	SC 13G
Feb 09, 2023	state street corp	8.22%	5,123,806	SC 13G/A

Recent SEC filings of Avid Bioservices Inc

View All Filings

Date Filed	Form Type	Document
May 02, 2024	4	Insider Trading
May 02, 2024	4	Insider Trading
May 02, 2024	4	Insider Trading
May 02, 2024	4	Insider Trading
May 02, 2024	4	Insider Trading
Apr 30, 2024	144	Notice of Insider Sale Intent
Apr 26, 2024	SC 13G	Major Ownership Report
Apr 25, 2024	8-K	Current Report
Apr 24, 2024	10-K/A	Annual Report
Apr 24, 2024	10-Q	Quarterly Report

Peers (Alternatives to Avid Bioservices Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	233.93%	75.07%	-4.57	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Avid Bioservices Inc News

Latest updates

Avid Bioservices Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	33.2%	33,815	25,395	37,726	39,799	38,018	34,757	36,692	31,226	31,508	26,109	30,754	27,606	21,806	21,064	25,392	12,550	13,585	18,313	15,254	17,055	13,781
Cost Of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	12,800	14,953	14,168	13,407	11,731
Gross Profit	151.1%	2,383	-4,665	4,100	8,391	9,825	4,147	9,117	6,984	9,087	9,186	11,391	8,143	6,202	6,418	8,544	-1,299	785	3,360	1,086	3,648	2,050
Costs and Expenses	-100.0%	-	6,557	6,263	7,559	7,107	6,831	6,382	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Expenses	-2.7%	6,382	6,557	6,263	-	7,107	6,831	6,382	-	5,818	5,033	4,460	-	4,018	4,166	-	-	2,996	3,889	-	-	3,242
S&GA Expenses	-2.7%	6,382	6,557	6,263	7,559	7,107	6,831	6,382	5,915	5,818	5,033	4,460	5,055	4,018	4,166	3,825	3,528	2,996	3,534	4,459	3,573	3,242
EBITDA Margin	-1396.7%	-0.06*	0.00*	0.05*	0.08*	0.08*	0.08*	0.13*	0.17*	0.16*	0.17*	0.17*	0.17*	-	-	-	-	-	-	-	-	-
Interest Expenses	5.8%	875	827	825	659	636	877	841	555	718	704	703	1,160	-	-	4.00	-	-	-	-	-	-
Income Taxes	55.9%	-1,052	-2,388	-608	4,675	-2,761	-2,896	-583	-115,011	-	-	-	-	-	-	-	-	-	-	-	-67.00	-44.00
Earnings Before Taxes	40.7%	-7,058	-11,909	-2,730	548	2,514	-3,416	1,944	587	2,248	3,522	6,304	-	-	-	-	-4,768	-2,104	-430	-	167	-1,183
EBT Margin	-88.3%	-0.15*	-0.08*	-0.02*	0.01*	0.02*	0.01*	0.07*	0.11*	0.10*	0.11*	0.11*	0.12*	-	-	-	-	-	-	-	-	-
Net Income	36.9%	-6,006	-9,521	-2,122	-335	-247	-520	1,361	115,598	2,248	3,522	6,304	1,991	2,207	2,284	4,730	-4,768	-2,104	-430	-3,164	336	-1,139
Net Income Margin	-51.6%	-0.13*	-0.09*	-0.02*	0.00*	0.83*	0.88*	0.98*	1.07*	0.12*	0.13*	0.13*	0.12*	-	-	-	-	-	-	-	-	-
Free Cashflow	34.6%	-801	-1,224	-14,392	-22,078	-18,244	-38,245	-11,958	-23,954	-14,829	2,978	-11,141	13,713	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-0.1%	455	455	443	452	451	443	451	430	314	302	271	266	168	114	106	108	105	105	102	78.00	76.00
Current Assets	-0.6%	104	104	98.00	112	132	146	181	180	203	207	201	208	116	63.00	57.00	60.00	57.00	56.00	52.00	51.00	49.00
Cash Equivalents	-2.3%	31.00	31.00	25.00	39.00	60.00	77.00	115	126	150	164	160	170	71.00	36.00	28.00	37.00	31.00	34.00	29.00	34.00	28.00
Inventory	-10.4%	35.00	39.00	41.00	44.00	45.00	39.00	30.00	26.00	21.00	20.00	15.00	12.00	12.00	10.00	10.00	11.00	10.00	8.00	8.00	7.00	9.00
Net PPE	-0.2%	188	188	183	178	164	139	115	93.00	69.00	52.00	45.00	37.00	32.00	30.00	28.00	27.00	27.00	27.00	26.00	26.00	26.00
Liabilities	1.1%	275	272	253	262	266	261	272	255	258	251	-	188	83.00	64.00	59.00	66.00	58.00	-	-	25.00	-
Current Liabilities	1.6%	223	219	206	215	228	223	94.00	76.00	77.00	70.00	63.00	71.00	63.00	44.00	38.00	44.00	37.00	34.00	29.00	23.00	21.00
Shareholder's Equity	-1.7%	180	183	190	189	185	182	179	175	57.00	51.00	45.00	78.00	85.00	49.00	47.00	42.00	47.00	49.00	50.00	53.00	53.00
Retained Earnings	-1.4%	-448	-442	-433	-431	-430	-430	-430	-431	-546	-549	-552	-559	-561	-564	-566	-571	-566	-564	-563	-560	-560
Additional Paid-In Capital	0.5%	629	626	623	620	616	612	609	606	603	600	597	638	647	613	613	613	613	613	613	614	614
Accumulated Depreciation	7.9%	38.00	36.00	33.00	30.00	-	-	-	24.00	-	-	-	-	-	-	-	-	-	-	-	-	-
Shares Outstanding	0.4%	63.00	63.00	63.00	63.00	62.00	62.00	62.00	62.00	61.00	61.00	61.00	58.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	-	-	887	-	-	-	1,900	-	-	-	409	-	-	-	301	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-41.0%	3,687	6,244	-236	3,145	-6,941	-3,837	-5,089	612	5,192	10,603	-6,942	17,860	5,189	10,406	-2,273	3,047	-636	5,884	-2,468	5,648	-3,082
Share Based Compensation	-0.3%	2,459	2,466	2,343	3,551	2,744	2,786	1,897	2,028	2,111	1,942	1,299	1,100	999	1,025	730	650	595	651	603	515	458
Cashflow From Investing	39.9%	-4,488	-7,468	-14,156	-25,223	-11,303	-34,408	-6,869	-24,566	-20,021	-7,625	-4,199	-4,147	-2,737	-2,491	-489	-787	-2,040	-947	-38.00	-208	-802
Cashflow From Financing	-98.9%	85.00	7,400	748	704	868	400	929	163	1,111	1,005	918	85,308	32,778	-462	-5,289	3,315	-597	-721	-901	-847	-1,052

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

CDMO Income Statement

2023-07-31

CONDENSED CONSOLIDATED STATEMENTS OF INCOME (LOSS) AND COMPREHENSIVE INCOME (LOSS) (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Jul. 31, 2023	Jul. 31, 2022
Income Statement [Abstract]
Revenues	$ 37,726	$ 36,692
Cost of revenues	33,626	27,575
Gross profit	4,100	9,117
Operating expenses:
Selling, general and administrative	6,263	6,382
Total operating expenses	6,263	6,382
Operating income (loss)	(2,163)	2,735
Interest expense	(825)	(841)
Other income (expense), net	258	50
Net income (loss) before income taxes	(2,730)	1,944
Income tax expense (benefit)	(608)	583
Net income (loss)	(2,122)	1,361
Comprehensive income (loss)	$ (2,122)	$ 1,361
Net income (loss) per share:
Basic	$ (0.03)	$ 0.02
Diluted	$ (0.03)	$ 0.02
Weighted average common shares outstanding:
Basic	62,838	61,905
Diluted	62,838	63,333

CDMO Balance Sheet

2023-07-31

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($) $ in Thousands	Jul. 31, 2023	Apr. 30, 2023	Jul. 31, 2022	Apr. 30, 2022
Current assets:
Cash and cash equivalents	$ 24,898	$ 38,542	$ 115,137	$ 126,166
Accounts receivable, net	16,209	18,298
Contract assets	14,454	9,609
Inventory	40,866	43,908
Prepaid expenses and other current assets	1,892	2,094
Total current assets	98,319	112,451
Property and equipment, net	182,835	177,770
Operating lease right-of-use assets	42,374	42,772
Deferred tax assets	114,371	113,751
Other assets	4,757	4,473
Restricted cash	350	350	350	350
Total assets	443,006	451,567
Current liabilities:
Accounts payable	22,813	24,593
Accrued compensation and benefits	4,667	8,780
Contract liabilities	33,019	37,352
Convertible senior notes, net	140,888	140,623
Current portion of operating lease liabilities	1,262	1,358
Other current liabilities	3,295	2,440
Total current liabilities	205,944	215,146
Operating lease liabilities, less current portion	45,370	45,690
Finance lease liabilities, less current portion	1,424	1,562
Total liabilities	252,738	262,398
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $0.001 par value; 5,000 shares authorized; no shares issued and outstanding at respective dates	0	0
Common stock, $0.001 par value; 150,000 shares authorized; 63,111 and 62,692 shares issued and outstanding at respective dates	63	63
Additional paid-in capital	623,445	620,224
Accumulated deficit	(433,240)	(431,118)
Total stockholders’ equity	190,268	189,169	$ 178,796	$ 174,526
Total liabilities and stockholders’ equity	$ 443,006	$ 451,567

About Avid Bioservices Inc

Avid Bioservices, Inc., a contract development and manufacturing organization, provides process development and current good manufacturing practices (CGMP) clinical and commercial manufacturing services of biologics for the biotechnology and biopharmaceutical industries. The company offers various services, including clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing, and regulatory submission and support. It also provides various process development services, such as upstream and downstream development and optimization, analytical methods development, cell line development, testing, and characterization. The company was formerly known as Peregrine Pharmaceuticals, Inc. and changed its name to Avid Bioservices, Inc. in January 2018. Avid Bioservices, Inc. was incorporated in 1981 and is headquartered in Tustin, California.

CEO	Mr. Nicholas Stewart Green B.Sc., MBA
WEBSITE	avidbio.com
INDUSTRY	Biotechnology
EMPLOYEES	365

Avid Bioservices Inc Frequently Asked Questions

What is the ticker symbol for Avid Bioservices Inc? What does CDMO stand for in stocks?

CDMO is the stock ticker symbol of Avid Bioservices Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Avid Bioservices Inc (CDMO)?

As of Fri May 17 2024, market cap of Avid Bioservices Inc is 578.94 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CDMO stock?

You can check CDMO's fair value in chart for subscribers.

What is the fair value of CDMO stock?

You can check CDMO's fair value in chart for subscribers. The fair value of Avid Bioservices Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Avid Bioservices Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for CDMO so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Avid Bioservices Inc a good stock to buy?

The fair value guage provides a quick view whether CDMO is over valued or under valued. Whether Avid Bioservices Inc is cheap or expensive depends on the assumptions which impact Avid Bioservices Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CDMO.

What is Avid Bioservices Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, CDMO's PE ratio (Price to Earnings) is -32.19 and Price to Sales (PS) ratio is 4.23. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CDMO PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Avid Bioservices Inc's stock?

In the past 10 years, Avid Bioservices Inc has provided -0.027 (multiply by 100 for percentage) rate of return.